• Selected as 2022 Advanced Regenerative Medicine Clinical Study Support Project
    Author : 관리자
    Date : 2022.03.17
    Hit : 500





  • - First in Korea to receive approval for advanced regenerative medicine clinical study in the moderate risk field

    - Will research ""strategies for maximizing treatment effects for patients with lymphoma with a high rate of recurrence""


    The research team led by Professor Cho Seok-gu (Department of Hematology, Director of Research and Head of the Industry-Academic Cooperation Group), the Head of the Translational Medicine Molecular Imaging Research Institute at the School of Medicine at the Catholic University of Korea, was selected for the ""2022 Advanced Regenerative Medicine Clinical Study Support Project"" hosted by the Ministry of Health and Welfare.


    The team will receive a total of 1 billion won for research support over the course of 2 years to conduct ""An Investigator’s Initiated Trial to Evaluate the Safety of Cytokine-Induced Killers during Early Transplant Period of Autologous Hematopoeitic Stem Cell Transplant Recipients.""


    This is a meaningful selection in that it is the first time a university hospital in Korea has received approval for an advanced regenerative medicine clinical study in the moderate risk field since the enforcement of the ""Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products.""


    Professor Cho Seok-gu, who is the principal investigator of this study, stated, ""Because there is currently no treatment for patients with lymphoma who received auto-transplantation after remission, this clinical protocol can be considered the first of its kind in the world. If we succeed in developing a treatment through this study, we will be able to expand it to various tumor fields and create additional values toward improving medical treatment."""



  • Attachment File
Comment 0